Literature DB >> 12526873

Remifentanil.

Paula Mason1.   

Abstract

Remifentanil is a synthetic opioid receptor agonist that was introduced in 1997 for analgesia during general anaesthesia. However, it recently received a license for analgesia and sedation in ventilated intensive care patients and so is now of interest to those working in intensive care.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12526873     DOI: 10.1016/s0964-3397(02)00087-3

Source DB:  PubMed          Journal:  Intensive Crit Care Nurs        ISSN: 0964-3397            Impact factor:   3.072


  7 in total

Review 1.  Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Spotlight on remifentanil: its analgesic and sedative use in the intensive care unit.

Authors:  Anna J Battershill; Gillian M Keating
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  Spotlight on remifentanil for general anaesthesia.

Authors:  Lesley J Scott; Caroline M Perry
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Effects of remifentanyl and fentanyl on LPS-induced cytokine release in human whole blood in vitro.

Authors:  Yun Wu; Yanlin Wang; Jia Zhan
Journal:  Mol Biol Rep       Date:  2008-06-25       Impact factor: 2.316

5.  Remifentanil attenuates lipopolysaccharide-induced acute lung injury by downregulating the NF-κB signaling pathway.

Authors:  Ying Zhang; Zhaohui Du; Qing Zhou; Yanlin Wang; Jianguo Li
Journal:  Inflammation       Date:  2014-10       Impact factor: 4.092

6.  Protective effects of remifentanil on septic mice.

Authors:  Zhang Zongze; Zhan Jia; Chen Chang; Chen Kai; Wang Yanlin
Journal:  Mol Biol Rep       Date:  2009-09-15       Impact factor: 2.316

Review 7.  Remifentanil : a review of its analgesic and sedative use in the intensive care unit.

Authors:  Anna J Battershill; Gillian M Keating
Journal:  Drugs       Date:  2006       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.